placebo in COVID-19 severe or critically - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results CAP-China (Wang et al.), 2020 (REV) 0.91 [0.41; 2.03]
0.91 [0.41 ; 2.03 ] CAP-China (Wang et al.), 2020 (REV) 1 0% 236 NA not evaluable clinical deteriorationdetailed results CAP-China (Wang et al.), 2020 (REV) 1.05 [0.61; 1.82]
1.05 [0.61 ; 1.82 ] CAP-China (Wang et al.), 2020 (REV) 1 0% 237 NA not evaluable clinical improvementdetailed results CAP-China (Wang et al.), 2020 (REV) 0.81 [0.57; 1.15]
0.81 [0.57 ; 1.15 ] CAP-China (Wang et al.), 2020 (REV) 1 0% 237 NA not evaluable clinical improvement (14-day)detailed results CAP-China (Wang et al.), 2020 (REV) 0.83 [0.44; 1.56]
0.83 [0.44 ; 1.56 ] CAP-China (Wang et al.), 2020 (REV) 1 0% 236 NA not evaluable clinical improvement (28-day)detailed results CAP-China (Wang et al.), 2020 (REV) 0.73 [0.42; 1.27]
0.73 [0.42 ; 1.27 ] CAP-China (Wang et al.), 2020 (REV) 1 0% 236 NA not evaluable clinical improvement (7-day)detailed results CAP-China (Wang et al.), 2020 (REV) 1.01 [0.18; 5.66]
1.01 [0.18 ; 5.66 ] CAP-China (Wang et al.), 2020 (REV) 1 0% 236 NA not evaluable clinical improvement (time to event analysis only)detailed results CAP-China (Wang et al.), 2020 (REV) 0.81 [0.57; 1.15]
0.81 [0.57 ; 1.15 ] CAP-China (Wang et al.), 2020 (REV) 1 0% 237 NA not evaluable AE leading to drug discontinuationdetailed results CAP-China (Wang et al.), 2020 (REV) 0.41 [0.13; 1.26]
0.41 [0.13 ; 1.26 ] CAP-China (Wang et al.), 2020 (REV) 1 0% 233 NA not evaluable serious adverse eventsdetailed results CAP-China (Wang et al.), 2020 (REV) 1.56 [0.81; 3.00]
1.56 [0.81 ; 3.00 ] CAP-China (Wang et al.), 2020 (REV) 1 0% 233 NA not evaluable deep vein thrombosisdetailed results CAP-China (Wang et al.), 2020 (REV) 2.00 [0.12; 32.41]
2.00 [0.12 ; 32.41 ] CAP-China (Wang et al.), 2020 (REV) 1 0% 233 NA not evaluable elevated liver enzymesdetailed results CAP-China (Wang et al.), 2020 (REV) 2.76 [0.99; 7.71]
2.76 [0.99 ; 7.71 ] CAP-China (Wang et al.), 2020 (REV) 1 0% 233 NA not evaluable hyperbilirubinemiadetailed results CAP-China (Wang et al.), 2020 (REV) 0.92 [0.36; 2.36]
0.92 [0.36 ; 2.36 ] CAP-China (Wang et al.), 2020 (REV) 1 0% 233 NA not evaluable pulmonary embolismdetailed results CAP-China (Wang et al.), 2020 (REV) 2.00 [0.12; 32.41]
2.00 [0.12 ; 32.41 ] CAP-China (Wang et al.), 2020 (REV) 1 0% 233 NA not evaluable renal impairmentdetailed results CAP-China (Wang et al.), 2020 (REV) 0.99 [0.03; 29.94]
0.99 [0.03 ; 29.94 ] CAP-China (Wang et al.), 2020 (REV) 1 0% 233 NA not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-08-10 21:47 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
